Profile
Masayuki Kobayashi is Chairman at Taiho Oncology, Inc. since 2014, President & Representative Director at Taiho Pharmaceutical Co., Ltd. since 2012, and Director at Otsuka Holdings Co., Ltd. since 2017.
Formerly, Mr. Kobayashi was Chief Executive Officer at Otsuka America, Inc.
Masayuki Kobayashi active positions
| Companies | Position | Start |
|---|---|---|
| OTSUKA HOLDINGS CO., LTD. | Director/Board Member | 30/03/2017 |
Taiho Pharmaceutical Co., Ltd.
Taiho Pharmaceutical Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Develops oncology drugs | President | 03/04/2012 |
Taiho Oncology, Inc.
Taiho Oncology, Inc. Pharmaceuticals: MajorHealth Technology Engages in development and commercialization of orally administered anti-cancer agents for tumor types | Chairman | 01/04/2014 |
Former positions of Masayuki Kobayashi
| Companies | Position | End |
|---|---|---|
Otsuka America, Inc.
Otsuka America, Inc. Pharmaceuticals: MajorHealth Technology Operates as a holding company whose subsidiaries manufactures and sells pharmaceutical, nutraceutical products & consumer markets | President | 31/03/2012 |
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 4 |
|---|---|
Taiho Pharmaceutical Co., Ltd.
Taiho Pharmaceutical Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Develops oncology drugs | Commercial Services |
Otsuka America, Inc.
Otsuka America, Inc. Pharmaceuticals: MajorHealth Technology Operates as a holding company whose subsidiaries manufactures and sells pharmaceutical, nutraceutical products & consumer markets | Health Technology |
Otsuka Holdings Co., Ltd.
Otsuka Holdings Co., Ltd. Pharmaceuticals: MajorHealth Technology Operates as an investment holding company with interests in pharmaceutical preparations | Health Technology |
Taiho Oncology, Inc.
Taiho Oncology, Inc. Pharmaceuticals: MajorHealth Technology Engages in development and commercialization of orally administered anti-cancer agents for tumor types | Health Technology |
- Stock Market
- Insiders
- Masayuki Kobayashi
















